Benitec Biopharma Inc. (BNTC) Stock Analysis
Momentum Cont setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.22: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality. (Note: Risk dimension 4.6/10 and A.R:R 4.7:1 are different metrics that happen to read the same number here.)
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate... Read more
Sell if holding. Engine safety override at $13.22: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality. (Note: Risk dimension 4.6/10 and A.R:R 4.7:1 are different metrics that happen to read the same number here.) Chart setup: Trend continuation, RSI 67, MACD bullish. Score 5.4/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.22: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality. (Note: Risk dimension 4.6/10 and A.R:R 4.7:1 are different metrics that happen to read the same number here.) Chart setup: Trend continuation, RSI 67, MACD bullish. Prior stop was $12.29. Score 5.4/10, moderate confidence.
Take-profit target: $22.45 (+69.8% upside). Prior stop was $12.29. Stop-loss: $12.29.
Quality below floor (1.5 < 4.0).
Benitec Biopharma Inc. trades at a P/E of N/A (forward -1.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
13 analysts cover BNTC with a consensus score of 4.3/5. Average price target: $26.
What does Benitec Biopharma Inc. do?Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines....
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.